Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis.

To determine the impact of tumor progression on the reversibility of Neu-induced tumorigenesis, we have used the tetracycline regulatory system to conditionally express activated Neu in the mammary epithelium of transgenic mice. When induced with doxycycline, bitransgenic MMTV-rtTA/TetO-NeuNT mice develop multiple invasive mammary carcinomas, essentially all of which regress to a clinically undetectable state following transgene deinduction. This demonstrates that Neu-initiated tumorigenesis is reversible. Strikingly, extensive lung metastases arising from Neu-induced mammary tumors also rapidly and fully regress following the abrogation of Neu expression. However, despite the near universal dependence of both primary tumors and metastases on Neu transgene expression, most animals bearing fully regressed Neu-induced tumors ultimately develop recurrent tumors that have progressed to a Neu-independent state.

[1]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[2]  R. Cardiff,et al.  The Comparative Pathology of Human and Mouse Mammary Glands , 2004, Journal of Mammary Gland Biology and Neoplasia.

[3]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  G. Hortobagyi,et al.  Targeting HER2: recent developments and future directions for breast cancer patients. , 2001, Seminars in oncology.

[5]  M. Hung,et al.  HER2 overexpression and cancer targeting. , 2001, Seminars in oncology.

[6]  Kenneth Chu,et al.  Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC , 2002, Science.

[7]  B. Groner,et al.  Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. , 1988, Cancer research.

[8]  G. Hortobagyi Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. , 2001, Seminars in oncology.

[9]  L. Chin,et al.  Essential role for oncogenic Ras in tumour maintenance , 1999, Nature.

[10]  H. Varmus,et al.  Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. , 2001, Genes & development.

[11]  L. Chodosh,et al.  Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammary epithelial cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[12]  R. Cardiff,et al.  Mammary Disease Mice Model Premalignant Polyoma Middle-T Transgenic Updated Version , 2001 .

[13]  D. Tenen,et al.  Reversibility of acute B-cell leukaemia induced by BCR–ABL1 , 2000, Nature Genetics.

[14]  R. Cardiff,et al.  Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[15]  R. Cardiff,et al.  c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations , 2001, Nature Medicine.

[16]  D. Felsher,et al.  Reversible tumorigenesis by MYC in hematopoietic lineages. , 1999, Molecular cell.

[17]  R. Cardiff,et al.  The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting‡ , 2000, Oncogene.

[18]  P. Leder,et al.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.

[19]  P. Jolicoeur,et al.  Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene , 1989, Cell.

[20]  Robert B Boxer,et al.  A novel doxycycline‐inducible system for the transgenic analysis of mammary gland biology , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  G. Evan,et al.  Suppression of Myc-Induced Apoptosis in β Cells Exposes Multiple Oncogenic Properties of Myc and Triggers Carcinogenic Progression , 2002, Cell.

[23]  D Tripathy,et al.  Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Cori Bargmann,et al.  Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185 , 1986, Cell.

[25]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[26]  R. Cardiff,et al.  Transgenic mouse models of mammary tumorigenesis. , 1993, Cancer surveys.